Review



mouse anti synaptophysin syn  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Santa Cruz Biotechnology mouse anti synaptophysin syn

    Mouse Anti Synaptophysin Syn, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 361 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/SYP+Antibody/pmc13657354-8-0-4
    Average 96 stars, based on 361 article reviews
    mouse anti synaptophysin syn - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "TXNRD1-driven enteric glial remodeling promotes neuronal dysfunction in Hirschsprung disease"

    Article Title: TXNRD1-driven enteric glial remodeling promotes neuronal dysfunction in Hirschsprung disease

    Journal: iScience

    doi: 10.1016/j.isci.2026.117636


    Figure Legend Snippet:

    Techniques Used: Model Organisms, Recombinant, CCK-8 Assay, Apoptosis Assay, ROS Assay, Calcium Assay, Enzyme-linked Immunosorbent Assay, Generated, Software, Genotyping

    Related Articles

    other:

    Article Title: Unraveling α-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson's disease
    Article Snippet: We adapt Ultra-TC treated 384 well imaging plate (WP384-4BCCSH, QINGDAO AMA Co. LTD., China) as the carrier of immunoprecipitation, the thickness of its transparent bottom is less than 0.2 mm.

    Bioprocessing:

    Article Title: Possible regulation of the immune modulator tetraspanin CD81 by alpha-synuclein in melanoma.
    Article Snippet: Protein band intensities were measured using a BioRad Chemi-doc system, and intensities were normalized to the loading control α-Tubulin. .. We used the following mouse primary monoclonal antibodies: anti human CD81 (1:500, Santa Cruz, sc-166029), CD63 (1:500, Abcam, ab59479), HSP70/HSP72 (1:1000, Enzo, C92F3A-5), α-syn (1:1000, Santa Cruz, sc-12767), α-Tubulin (1:4000, Sigma Aldrich, T9026). .. We used the following rabbit primary polyclonal antibodies: human CD9 (1:500, Systems Bioscience, # EXOAB-CD9A-1), HSP90 Antibody (1:1000, Cell Signaling Technology #4874).

    Fluorescence:

    Article Title: Unraveling α-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson's disease
    Article Snippet: .. The fluorescence antibody was based on the most common-used detection antibody of the protein aggregate of α-syn (sc-12767, Santa Cruz biotechnology, USA) or amylin (sc-377530, Santa Cruz biotechnology, USA). ..

    Incubation:

    Article Title: Stereotactic infusion of rotenone into the SN induced a late-stage model of Parkinson's disease.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Article Title: Comparative proteomic analysis of plasma exosomes reveals the functional contribution of N-acetyl-alpha-glucosaminidase to Parkinson’s disease
    Article Snippet: .. The sections were then incubated with antibodies to tyrosine hydroxylase (TH) (rabbit, 1:200, Abcam, Cat# ab137869, RRID: AB_2801410), NAGLU (rabbit, 1:500, Abcam, Cat# ab214671), and α-syn (mouse, 1:200, Santa Cruz Biotechnology, Cat# sc-53955, RRID: AB_831743). .. After washing two times with PBS, the samples were incubated with Alexa Fluor 594–conjugated donkey anti-mouse (1:400, Invitrogen, Cat# A21203, RRID: AB_141633) and Alexa Fluor 594–conjugated donkey anti-rabbit (1:300, Invitrogen, Cat# A21207, RRID: AB_141637) secondary antibodies for 2 hours in the dark at room temperature.

    Modification:

    Article Title: Improved Imaging Surface for Quantitative Single-Molecule Microscopy.
    Article Snippet: .. Antibody and aptamer used in the work Data in Item Information Figure 2,3 AF647 IgG antibody MOPC-21 ,AB_2539542, Invitrogen Figure 2, S7 AF647 DNA aptamer (T- SO508) AF647-T-SO508, ATDbio Figure4(A),4(C),5,S7,S8,S9, S10 AF647 α-syn antibody(211) sc-12767 AF647,santa cruz biotech Figure 2 AF647Aβ antibody(6E10) 803020,biolegend Figure 2, 4(A),S3,S4 AF647 tau antibody(HT7)* MN1000,Invitrogen, with modification Figure 2 AF647 p53 antibody sc-12767 AF647,santa cruz biotech Figure4(A),4(C),5,S1,S5,S7,S8, S9,S10 Biotin α-syn antibody(211)* sc-12767, santa cruz biotech, with modification Figure4(A),S3 Biotin tau antibody(HT7) MN1000B,Invitrogen Figure4(B) Biotin α-syn antibody(211)* sc-1276, santa cruz biotech, with modification Figure4(B),S10 DNA-labelled α-syn antibody(211)* sc-1276, santa cruz biotech, with modification Figure4(C),S1,S5 Biotin α-syn antibody(MJFR14) ab216309, abcam Figure4(C) AF647 α-syn antibody(MJFR14) ab227047, abcam FigureS1 α-syn antibody(211)* sc-12767, santa cruz biotech FigureS1,S5 AF647 anti-mouse IgG ab150115 FigureS1 AF568 anti-mouse IgG ab175473 FigureS1 AF488 anti-mouse IgG ab150105 Figure4(C) Biotin α-syn antibody(LB509) 807710, biolegend Figure4(C) AF647 α-syn antibody(LB509) sc-58480 AF647 Figure4(D) AF647 CD81 Antibody FAB4615B Figure4(D) Biotin CD63 Antibody A85980 *Modifications including dye labelling and biotinylation Table S2. ..



    Similar Products

    92
    Novus Biologicals rabbit polyclonal anti synaptophysin syn
    Rabbit Polyclonal Anti Synaptophysin Syn, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/Synaptophysin+Antibody+(SP11)/pm42962661-832-110-114
    Average 92 stars, based on 1 article reviews
    rabbit polyclonal anti synaptophysin syn - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse anti synaptophysin syn

    Mouse Anti Synaptophysin Syn, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/SYP+Antibody/pmc13657354-8-0-4
    Average 96 stars, based on 1 article reviews
    mouse anti synaptophysin syn - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc antibodies against pser129 α syn

    Antibodies Against Pser129 α Syn, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/Phospho-alpha-Synuclein+(Ser129)+Rabbit+mAb/pm42624301-69-35-39
    Average 96 stars, based on 1 article reviews
    antibodies against pser129 α syn - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    Alomone Labs α syn
    Antibodies used for in vitro investigations.
    α Syn, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/Guinea+Pig+Anti-Alpha-Synuclein+Antibody/pmc13626330-5-0-7
    Average 94 stars, based on 1 article reviews
    α syn - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Proteintech mouse α syn
    Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic <t>flux,</t> <t>α-synuclein</t> <t>(α-syn)</t> and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.
    Mouse α Syn, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/alpha-synuclein+Antibody/pmc13658160-265-73-76
    Average 95 stars, based on 1 article reviews
    mouse α syn - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology anti glutamine synthetase gs
    Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic <t>flux,</t> <t>α-synuclein</t> <t>(α-syn)</t> and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.
    Anti Glutamine Synthetase Gs, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/Gl+Syn+Antibody/10__1038_slash_s41598___026___73640___2-54-14-19
    Average 93 stars, based on 1 article reviews
    anti glutamine synthetase gs - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    Twist Bioscience alpha
    Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic <t>flux,</t> <t>α-synuclein</t> <t>(α-syn)</t> and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.
    Alpha, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/Twist+Synthetic+SARS-CoV-2+RNA+Control/pm42549572-380-24-25
    Average 96 stars, based on 1 article reviews
    alpha - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    90
    Sino Biological alpha-synuclein protein
    Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic <t>flux,</t> <t>α-synuclein</t> <t>(α-syn)</t> and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.
    Alpha Synuclein Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/Alpha-synuclein+Protein/custom%40s22-30h%4042517556
    Average 90 stars, based on 1 article reviews
    alpha-synuclein protein - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    ABclonal Biotechnology α syn
    Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic <t>flux,</t> <t>α-synuclein</t> <t>(α-syn)</t> and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.
    α Syn, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1+syn/alpha+%2B+beta+Synuclein+Rabbit+mAb/pm41791449-33-10-25
    Average 90 stars, based on 1 article reviews
    α syn - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Journal: iScience

    Article Title: TXNRD1-driven enteric glial remodeling promotes neuronal dysfunction in Hirschsprung disease

    doi: 10.1016/j.isci.2026.117636

    Figure Lengend Snippet:

    Article Snippet: Mouse anti-Synaptophysin (SYN) , Santa Cruz Biotechnology , Cat# sc-365488.

    Techniques: Model Organisms, Recombinant, CCK-8 Assay, Apoptosis Assay, ROS Assay, Calcium Assay, Enzyme-linked Immunosorbent Assay, Generated, Software, Genotyping

    Antibodies used for in vitro investigations.

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: Antibodies used for in vitro investigations.

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: In Vitro

    Body mass evolution during 35 days of daily treatment with vehicle or AZP2006 post-lesion (A). Representative IHC images TH (red)/α-syn (green)/Iba1 (purple) (B). IHC analysis shows the total number of TH(+) neurons (C), area of α-syn accumulation in TH(+) neurons (D) and the number of Iba1(+) microglia in the SNpc (E) expressed as % of sham. Raw values for sham (i.e., 100%); TH(+) neurons = 65 ± 1.6; α-syn area/TH(+) neuron = 168 ± 9.4 µm 2 ; Iba1(+) cells = 53 ± 2.8. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01 or #### p < 0.0001 from sham; **p < 0.01; ***p < 0.001 and ****p < 0.0001 from α-syn+vehicle injury, (n = 7 mice / group).

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: Body mass evolution during 35 days of daily treatment with vehicle or AZP2006 post-lesion (A). Representative IHC images TH (red)/α-syn (green)/Iba1 (purple) (B). IHC analysis shows the total number of TH(+) neurons (C), area of α-syn accumulation in TH(+) neurons (D) and the number of Iba1(+) microglia in the SNpc (E) expressed as % of sham. Raw values for sham (i.e., 100%); TH(+) neurons = 65 ± 1.6; α-syn area/TH(+) neuron = 168 ± 9.4 µm 2 ; Iba1(+) cells = 53 ± 2.8. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01 or #### p < 0.0001 from sham; **p < 0.01; ***p < 0.001 and ****p < 0.0001 from α-syn+vehicle injury, (n = 7 mice / group).

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: Analysis

    ICC analysis of cultures shows the total number of TH(+) neurons (A,E), the length of their neurite network (B,F), the area of cytoplasmic α-syn staining per TH(+) neuron (C,G) and the area of the post-synaptic marker PSD95 per TH(+) neuron (D and H), expressed as % of control (CTR). Raw values for CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 27 ± 1.0; neurite network = 3540 ± 127 µm; α-syn area/TH(+) neuron = 201 ± 8.9 µm 2 ; PSD95 area/TH(+) neuron = 1829 ± 105 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01; ### p < 0.001 or #### p < 0.0001 from CTR (control) or from anti-PGRN Ab and *p < 0.05 or ****p < 0.0001 from 6OHDA or from 6OHDA + anti-PGRN Ab; (n = 4-6 / group).

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A,E), the length of their neurite network (B,F), the area of cytoplasmic α-syn staining per TH(+) neuron (C,G) and the area of the post-synaptic marker PSD95 per TH(+) neuron (D and H), expressed as % of control (CTR). Raw values for CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 27 ± 1.0; neurite network = 3540 ± 127 µm; α-syn area/TH(+) neuron = 201 ± 8.9 µm 2 ; PSD95 area/TH(+) neuron = 1829 ± 105 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01; ### p < 0.001 or #### p < 0.0001 from CTR (control) or from anti-PGRN Ab and *p < 0.05 or ****p < 0.0001 from 6OHDA or from 6OHDA + anti-PGRN Ab; (n = 4-6 / group).

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: Analysis, Staining, Marker, Control

    ICC analysis of cultures shows the total number of TH(+) neurons (A,E), the length of their neurite network (B,F), the area of cytoplasmic α-syn per TH(+) neuron (C,G) and lysosome burden as area of LAMP2(+) vesicles per TH(+) neuron (D and H), expressed as % of control (CTR). Raw values for MPP + & Rotenone CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 18 ± 0.5 & 26 ± 1; neurite network = 889 ± 57 & 929 ± 24 µm; α-syn area/TH(+) neuron = 29 ± 2.1 & 28 ± 1 µm 2 ; ratio LAMP2/TH(+) = 10 ± 0.3 & 10 ± 0.5, respectively. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. #### p < 0.0001 from CTR and *p < 0.05, **p < 0.01; ***p < 0.001 or ****p < 0.0001 from MPP + or Rotenone treatment, (n = 4-6 / group).

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A,E), the length of their neurite network (B,F), the area of cytoplasmic α-syn per TH(+) neuron (C,G) and lysosome burden as area of LAMP2(+) vesicles per TH(+) neuron (D and H), expressed as % of control (CTR). Raw values for MPP + & Rotenone CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 18 ± 0.5 & 26 ± 1; neurite network = 889 ± 57 & 929 ± 24 µm; α-syn area/TH(+) neuron = 29 ± 2.1 & 28 ± 1 µm 2 ; ratio LAMP2/TH(+) = 10 ± 0.3 & 10 ± 0.5, respectively. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. #### p < 0.0001 from CTR and *p < 0.05, **p < 0.01; ***p < 0.001 or ****p < 0.0001 from MPP + or Rotenone treatment, (n = 4-6 / group).

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: Analysis, Control

    ICC analysis of cultures shows the total number of TH(+) neurons (A), the length of their neurite network (B), the area of cytoplasmic α-syn staining per neuron (C), the area of LAMP2(+) staining per TH(+) neuron (D), the α-syn accumulation in lysosomes as α-syn/LAMP2 colocalization area (E), autophagosomes as LC3b(+) vesicles per TH(+) neuron (F), autolysosomes as LC3b(+) vesicles colocalized with LAMP2 area in TH(+) neurons (G), and functional lysosomes expressed as area of PhenoVue 577(+) staining per SH-SY5Y cell (H), expressed as % of control (CTR). Raw values for CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 32 ± 1.3; neurite network = 1054 ± 60.6 µm; α-syn area/TH(+) neuron = 25.2 ± 2.8 µm 2 ; LAMP2 area/TH(+) neurons = 17.9 ± 1.5 µm 2 ; α-syn area/LAMP2/TH(+) neuron = 4.4 ± 0.3 µm 2 ; LC3b area/TH(+) neurons = 27 ± 1.7 µm 2 ; LAMP2/LC3b area/TH(+) neurons = 7.8 ± 0.5 µm 2 ; PhenoVue 577(+) staining/SH-SY5Y cell = 67 ± 3.5 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 from the α-syn condition, (n = 5-6).

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A), the length of their neurite network (B), the area of cytoplasmic α-syn staining per neuron (C), the area of LAMP2(+) staining per TH(+) neuron (D), the α-syn accumulation in lysosomes as α-syn/LAMP2 colocalization area (E), autophagosomes as LC3b(+) vesicles per TH(+) neuron (F), autolysosomes as LC3b(+) vesicles colocalized with LAMP2 area in TH(+) neurons (G), and functional lysosomes expressed as area of PhenoVue 577(+) staining per SH-SY5Y cell (H), expressed as % of control (CTR). Raw values for CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 32 ± 1.3; neurite network = 1054 ± 60.6 µm; α-syn area/TH(+) neuron = 25.2 ± 2.8 µm 2 ; LAMP2 area/TH(+) neurons = 17.9 ± 1.5 µm 2 ; α-syn area/LAMP2/TH(+) neuron = 4.4 ± 0.3 µm 2 ; LC3b area/TH(+) neurons = 27 ± 1.7 µm 2 ; LAMP2/LC3b area/TH(+) neurons = 7.8 ± 0.5 µm 2 ; PhenoVue 577(+) staining/SH-SY5Y cell = 67 ± 3.5 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 from the α-syn condition, (n = 5-6).

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: Analysis, Staining, Functional Assay, Control

    ICC analysis of cultures shows the total number of TH(+) neurons (A) and the length of their neurite network neurons (B) and microglia activation as area of OX-41(+) staining (C), expressed as % of control. Raw values for control (CTR) (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 81 ± 4.0; neurite network = 2332 ± 112 µm; OX-41(+) area/field = 1421 ± 67 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; **p < 0.01, ***p < 0.001 and ****p < 0.0001 from α-syn injury, (n = 4-6 / group).

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A) and the length of their neurite network neurons (B) and microglia activation as area of OX-41(+) staining (C), expressed as % of control. Raw values for control (CTR) (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 81 ± 4.0; neurite network = 2332 ± 112 µm; OX-41(+) area/field = 1421 ± 67 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; **p < 0.01, ***p < 0.001 and ****p < 0.0001 from α-syn injury, (n = 4-6 / group).

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: Analysis, Activation Assay, Staining, Control

    ICC analysis shows the total number of cells (A, D), the area of cytoplasmic α-syn staining per cell (B,E) and lysosomal burden as area of LAMP2(+) vesicles per cell (C,F), expressed as % of control (CTR = PGRN KO alone in D-F). Raw values for PGRN KO CTR (i.e., 100%); cells/image field = 140 ± 3.9; α-syn area/cell = 38.1 ± 2.8 µm 2 ; LAMP2(+) area/cell = 51 ± 2.8 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01 or #### p < 0.0001 from CTR and *p < 0.05, **p < 0.01; ***p < 0.001 or ****p < 0.0001 from MPP + (n = 4-6 / group).

    Journal: PLOS One

    Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

    doi: 10.1371/journal.pone.0359269

    Figure Lengend Snippet: ICC analysis shows the total number of cells (A, D), the area of cytoplasmic α-syn staining per cell (B,E) and lysosomal burden as area of LAMP2(+) vesicles per cell (C,F), expressed as % of control (CTR = PGRN KO alone in D-F). Raw values for PGRN KO CTR (i.e., 100%); cells/image field = 140 ± 3.9; α-syn area/cell = 38.1 ± 2.8 µm 2 ; LAMP2(+) area/cell = 51 ± 2.8 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01 or #### p < 0.0001 from CTR and *p < 0.05, **p < 0.01; ***p < 0.001 or ****p < 0.0001 from MPP + (n = 4-6 / group).

    Article Snippet: α-syn , Guinea pig , Polyclonal , Alomone , APZ-035-GP , AB_2925147 , 3.

    Techniques: Analysis, Staining, Control

    Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic flux, α-synuclein (α-syn) and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.

    Journal: Frontiers in Aging Neuroscience

    Article Title: Clemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux

    doi: 10.3389/fnagi.2026.1915475

    Figure Lengend Snippet: Study and experimental flow chart. This Figure illustrates the overall experimental design and workflow of the study. The study integrates bioinformatic analyses with in vitro and in vivo experimental validations. Bioinformatic approaches included the single-cell transcriptome analysis of Parkinson’s disease (PD) patient midbrains to identify differentially expressed genes (DEGs) in dopaminergic neurons (DaNs) and cell type alterations, molecular docking between clemastine (CLE) and 22,618 proteins to identify potential targets, and correlation analysis between Braak staging and autophagy gene expression. The intersection of CLE targets and PD-related DEGs was used to predict the CLE’s mechanism of action, focusing on the AMPK/mTOR pathway and autophagy. These predictions were tested experimentally using an MPP + -induced PC12 cell model and a chronic MPTP-induced mouse model of PD. Endpoints assessed included protein expression (western blot and immunofluorescence), autophagic flux, α-synuclein (α-syn) and phosphorylated α-syn (p-α-syn) levels, dopaminergic neuron survival, motor function (rotarod test), and non-motor function (fecal pellet analysis). The integrative approach aims to demonstrate that CLE alleviates PD pathology by activating the AMPK/mTOR pathway, enhancing autophagic flux, and promoting the clearance of pathological α-syn. PD, Parkinson’s disease; CLE, Clemastine; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP + , 1-methyl-4-phenylpyridinium; DEGs, differentially expressed genes; DaNs, dopaminergic neurons; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; α-syn, α-synuclein; p-α-syn: phosphorylated α-synuclein.

    Article Snippet: Proteins were transferred to PVDF membranes at 30 V for 90 min. Membranes were blocked with 5% non-fat milk in PBST for 1 h and incubated with primary antibodies for 2 h at room temperature: 1:50,000 mouse GAPDH (60004-1-Ig, Proteintech), 1:2,000 mouse p-mTOR (Ser2448) (67778-1-Ig, Proteintech), 1:5,000 mouse t-mTOR (66888-1-Ig, Proteintech), 1:1000 rabbit p-AMPK (Thr183/172) (ab133448, Abcam), 1:1000 mouse p62 (66184-1-Ig, Proteintech), 1:1,000 rabbit LC3-I/II (orb411847, Biorbyt), 1:5,000 mouse P62 (66184-1-Ig, Proteintech), 1:500 mouse α-syn (66412-1-Ig, Proteintech).

    Techniques: In Vitro, In Vivo, Single Cell, Analysis, Docking Assay, Gene Expression, Expressing, Western Blot, Immunofluorescence, Pathology

    CLE reduces α-synuclein protein levels and improves cell survival, effects inhibited by dorsomorphin (DOR). (A) Western blot (WB) and (B) The quantification of α-synuclein (α-syn) protein levels in PC12 cells from CTRL, MPP + , CLE, and MPP + +CLE groups. GAPDH is shown as a loading control. (C) Cell survival rate in CTRL, MPP + , and MPP + +CLE groups. (D, G) The WB analysis of p-AMPK (Thr172), t-AMPK, p-mTOR (Ser2448), and t-mTOR protein levels in CTRL, DOR, CLE, and DOR+CLE groups. (E, F, H) The Quantification of the indicated protein ratios. Data are presented as mean ± SEM. Tukey’s multiple comparison test was performed after one-way ANOVA. * P < 0.05, ** P < 0.01 *** P < 0.001; ns, not significant. CLE, clemastine; α-syn, α-synuclein; CTRL, control; WB, western blot; DOR, dorsomorphin; ANOVA, analysis of variance; SEM, standard error of the mean. n = 5 independent experiments.

    Journal: Frontiers in Aging Neuroscience

    Article Title: Clemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux

    doi: 10.3389/fnagi.2026.1915475

    Figure Lengend Snippet: CLE reduces α-synuclein protein levels and improves cell survival, effects inhibited by dorsomorphin (DOR). (A) Western blot (WB) and (B) The quantification of α-synuclein (α-syn) protein levels in PC12 cells from CTRL, MPP + , CLE, and MPP + +CLE groups. GAPDH is shown as a loading control. (C) Cell survival rate in CTRL, MPP + , and MPP + +CLE groups. (D, G) The WB analysis of p-AMPK (Thr172), t-AMPK, p-mTOR (Ser2448), and t-mTOR protein levels in CTRL, DOR, CLE, and DOR+CLE groups. (E, F, H) The Quantification of the indicated protein ratios. Data are presented as mean ± SEM. Tukey’s multiple comparison test was performed after one-way ANOVA. * P < 0.05, ** P < 0.01 *** P < 0.001; ns, not significant. CLE, clemastine; α-syn, α-synuclein; CTRL, control; WB, western blot; DOR, dorsomorphin; ANOVA, analysis of variance; SEM, standard error of the mean. n = 5 independent experiments.

    Article Snippet: Proteins were transferred to PVDF membranes at 30 V for 90 min. Membranes were blocked with 5% non-fat milk in PBST for 1 h and incubated with primary antibodies for 2 h at room temperature: 1:50,000 mouse GAPDH (60004-1-Ig, Proteintech), 1:2,000 mouse p-mTOR (Ser2448) (67778-1-Ig, Proteintech), 1:5,000 mouse t-mTOR (66888-1-Ig, Proteintech), 1:1000 rabbit p-AMPK (Thr183/172) (ab133448, Abcam), 1:1000 mouse p62 (66184-1-Ig, Proteintech), 1:1,000 rabbit LC3-I/II (orb411847, Biorbyt), 1:5,000 mouse P62 (66184-1-Ig, Proteintech), 1:500 mouse α-syn (66412-1-Ig, Proteintech).

    Techniques: Western Blot, Control, Analysis, Comparison

    CLE increases AMPK phosphorylation, decreases mTOR phosphorylation at Ser2448, enhances autophagy, and reduces α-synuclein levels in the mouse midbrain. (A) The WB analysis of p-AMPK (Thr172), t-AMPK, p-mTOR (Ser2448), and t-mTOR protein levels in the midbrain of mice from CTRL, MPTP, and MPTP+CLE groups. GAPDH is shown as a loading control. (B) The quantification of p-mTOR/t-mTOR levels. (C) The quantification of p-AMPK/t-AMPK levels. (D–F) The WB analysis of p62, LC3-I/II, and α-syn protein levels. (G–I) The quantification of p62, LC3-II/LC3-I ratio, and α-syn protein levels. Data are presented as mean ± SEM. Tukey’s multiple comparison test was performed after one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001. CLE, clemastine; α-syn, α-synuclein; CTRL, control; WB, western blot; ANOVA, analysis of variance; SEM, standard error of the mean. n = 5 independent experiments.

    Journal: Frontiers in Aging Neuroscience

    Article Title: Clemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux

    doi: 10.3389/fnagi.2026.1915475

    Figure Lengend Snippet: CLE increases AMPK phosphorylation, decreases mTOR phosphorylation at Ser2448, enhances autophagy, and reduces α-synuclein levels in the mouse midbrain. (A) The WB analysis of p-AMPK (Thr172), t-AMPK, p-mTOR (Ser2448), and t-mTOR protein levels in the midbrain of mice from CTRL, MPTP, and MPTP+CLE groups. GAPDH is shown as a loading control. (B) The quantification of p-mTOR/t-mTOR levels. (C) The quantification of p-AMPK/t-AMPK levels. (D–F) The WB analysis of p62, LC3-I/II, and α-syn protein levels. (G–I) The quantification of p62, LC3-II/LC3-I ratio, and α-syn protein levels. Data are presented as mean ± SEM. Tukey’s multiple comparison test was performed after one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001. CLE, clemastine; α-syn, α-synuclein; CTRL, control; WB, western blot; ANOVA, analysis of variance; SEM, standard error of the mean. n = 5 independent experiments.

    Article Snippet: Proteins were transferred to PVDF membranes at 30 V for 90 min. Membranes were blocked with 5% non-fat milk in PBST for 1 h and incubated with primary antibodies for 2 h at room temperature: 1:50,000 mouse GAPDH (60004-1-Ig, Proteintech), 1:2,000 mouse p-mTOR (Ser2448) (67778-1-Ig, Proteintech), 1:5,000 mouse t-mTOR (66888-1-Ig, Proteintech), 1:1000 rabbit p-AMPK (Thr183/172) (ab133448, Abcam), 1:1000 mouse p62 (66184-1-Ig, Proteintech), 1:1,000 rabbit LC3-I/II (orb411847, Biorbyt), 1:5,000 mouse P62 (66184-1-Ig, Proteintech), 1:500 mouse α-syn (66412-1-Ig, Proteintech).

    Techniques: Phospho-proteomics, Analysis, Control, Comparison, Western Blot

    CLE increases LC3 and reduces phosphorylated α-synuclein in dopaminergic neurons (DaNs) of MPTP-treated mice. (A) Immunofluorescence staining for TH (red, marker for DaNs), LC3 (green), and DAPI (blue) in the substantia nigra (SN) of mice from CTRL, MPTP, and MPTP+CLE groups. Scale bar: 2 μm. (B) The quantification of the relative number of LC3 puncta in DaNs. (C) Immunofluorescence staining for TH (red), p-α-syn (Ser129, green), and DAPI (blue) in the SN. Scale bar: 5 μm. (D) The quantification of the relative fluorescence intensity of p-α-syn (Ser129) in DaNs. Data are presented as mean ± SEM (N = 21 per group). Tukey’s multiple comparison test was performed after one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001. CLE, clemastine; DaNs, dopaminergic neurons; p-α-syn, phosphorylated α-synuclein (Ser129); SN, substantia nigra; CTRL, control; ANOVA, analysis of variance; SEM, standard error of the mean. n = 21 images per group (7 images from 3 mice per group).

    Journal: Frontiers in Aging Neuroscience

    Article Title: Clemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux

    doi: 10.3389/fnagi.2026.1915475

    Figure Lengend Snippet: CLE increases LC3 and reduces phosphorylated α-synuclein in dopaminergic neurons (DaNs) of MPTP-treated mice. (A) Immunofluorescence staining for TH (red, marker for DaNs), LC3 (green), and DAPI (blue) in the substantia nigra (SN) of mice from CTRL, MPTP, and MPTP+CLE groups. Scale bar: 2 μm. (B) The quantification of the relative number of LC3 puncta in DaNs. (C) Immunofluorescence staining for TH (red), p-α-syn (Ser129, green), and DAPI (blue) in the SN. Scale bar: 5 μm. (D) The quantification of the relative fluorescence intensity of p-α-syn (Ser129) in DaNs. Data are presented as mean ± SEM (N = 21 per group). Tukey’s multiple comparison test was performed after one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001. CLE, clemastine; DaNs, dopaminergic neurons; p-α-syn, phosphorylated α-synuclein (Ser129); SN, substantia nigra; CTRL, control; ANOVA, analysis of variance; SEM, standard error of the mean. n = 21 images per group (7 images from 3 mice per group).

    Article Snippet: Proteins were transferred to PVDF membranes at 30 V for 90 min. Membranes were blocked with 5% non-fat milk in PBST for 1 h and incubated with primary antibodies for 2 h at room temperature: 1:50,000 mouse GAPDH (60004-1-Ig, Proteintech), 1:2,000 mouse p-mTOR (Ser2448) (67778-1-Ig, Proteintech), 1:5,000 mouse t-mTOR (66888-1-Ig, Proteintech), 1:1000 rabbit p-AMPK (Thr183/172) (ab133448, Abcam), 1:1000 mouse p62 (66184-1-Ig, Proteintech), 1:1,000 rabbit LC3-I/II (orb411847, Biorbyt), 1:5,000 mouse P62 (66184-1-Ig, Proteintech), 1:500 mouse α-syn (66412-1-Ig, Proteintech).

    Techniques: Immunofluorescence, Staining, Marker, Fluorescence, Comparison, Control, Analysis